CCR New Strategies New Strategies in Hodgkin Lymphoma: Better Risk Profiling and Novel Treatments

Recent advances in Hodgkin lymphoma research are expected to prelude a promising new treatment era for patients and their treating physicians. Scientific investigations over the last few years have provided new insights into risk stratification, and, simultaneously, a plethora of novel targeted therapies are emerging for patients with relapsed and refractory disease. These novel therapies will be tested primarily in high-risk patients because 75% of the patients are cured with conventional therapies. The challenges, as Hodgkin lymphoma therapy moves forward, will be using these biologic insights to identify the patients who may benefit earlier in treatment from these novel agents, and tailoring the therapy to the tumor biology of the patient. These dual aims are intertwined; as our therapeutic arsenal increases, these biologic determinants of risk may themselves inform the design of therapies and the choice of treatments for high-risk patients. Clin Cancer Res; 19(11); 2797–803. 2013 AACR. Disclosure of Potential Conflicts of Interest C. Diefenbach has honoraria from speakers’ bureau and is a consultant/advisory boardmember of Seattle Genetics. No potential conflicts of interest were disclosed by C. Steidl. CME Staff Planners' Disclosures The members of the planning committee have no real or apparent conflict of interest to disclose. Learning Objective(s) Upon completion of this activity, the participant should have a better understanding of the strategies currently under investigation to improve risk profiling in classical Hodgkin lymphoma, and of the biologic rationale underlying novel therapeutic strategies for patients with relapsed and refractory disease. Acknowledgment of Financial or Other Support This activity does not receive commercial support.